See more : Hong Yuan Holding Group (HGYN) Income Statement Analysis – Financial Results
Complete financial analysis of Acumen Pharmaceuticals, Inc. (ABOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acumen Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Toyota Motor Corporation (TM) Income Statement Analysis – Financial Results
- Maruti Suzuki India Limited (MARUTI.NS) Income Statement Analysis – Financial Results
- Ricoh Company, Ltd. (RICOY) Income Statement Analysis – Financial Results
- SunPower Corporation (0R0V.L) Income Statement Analysis – Financial Results
- VusionGroup (VU.PA) Income Statement Analysis – Financial Results
Acumen Pharmaceuticals, Inc. (ABOS)
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.44M | 1.70M |
| Cost of Revenue | 42.32M | 169.00K | 4.00K | 8.00K | 8.58K |
| Gross Profit | -42.32M | -169.00K | -4.00K | 1.43M | 1.69M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 99.44% | 99.49% |
| Research & Development | 42.32M | 32.36M | 12.31M | 8.00M | 8.58M |
| General & Administrative | 18.82M | 12.88M | 7.28M | 1.35M | 926.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.82M | 12.88M | 7.28M | 1.35M | 926.00K |
| Other Expenses | 0.00 | -11.00K | 51.00K | 0.00 | 0.00 |
| Operating Expenses | 61.14M | 45.24M | 19.58M | 9.35M | 9.50M |
| Cost & Expenses | 61.14M | 45.24M | 19.58M | 9.35M | 9.50M |
| Interest Income | 10.21M | 2.39M | 84.00K | 1.00K | 45.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 184.00K | 169.00K | 4.00K | 7.91M | 7.81M |
| EBITDA | -51.61M | -42.69M | 61.58M | 587.00K | 119.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -591.78% | -451.27% |
| Operating Income | -61.14M | -45.24M | 61.57M | -7.91M | -7.81M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -550.97% | -459.93% |
| Total Other Income/Expenses | 8.77M | 2.38M | -81.02M | 587.00K | -102.00K |
| Income Before Tax | -52.37M | -42.86M | -100.61M | -7.33M | -7.91M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -510.10% | -465.94% |
| Income Tax Expense | 0.00 | -2.38M | 81.07M | -1.00K | -45.00K |
| Net Income | -52.37M | -40.48M | -181.68M | -7.32M | -7.86M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -510.03% | -463.29% |
| EPS | -1.08 | -1.00 | -4.49 | -0.18 | -0.20 |
| EPS Diluted | -1.08 | -1.00 | -4.49 | -0.18 | -0.20 |
| Weighted Avg Shares Out | 48.49M | 40.60M | 40.47M | 40.15M | 40.15M |
| Weighted Avg Shares Out (Dil) | 48.61M | 40.60M | 40.47M | 40.15M | 40.15M |
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate...
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q3 2024 Results Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Braun - Head of Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer, Chief Business Officer...
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate...
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference
NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate...
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference
NEWTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today presented updated data on a...
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference
- Presentation to focus on use of validated pTau217 assay in participant screening process for Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer's disease
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
NEWTON, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate...
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD),...
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
NEWTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate...
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer, Chief Business Officer Dr. Jim Doherty - President, Chief Development...
Source: https://incomestatements.info
Category: Stock Reports